• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

    7/3/23 6:00:00 AM ET
    $BNOX
    $ORGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BNOX alert in real time by email
    • Alan Fisher appointed Chair of the Board of Directors
    • Tim Cunningham joins as Chief Financial Officer

    ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth.

    Alan Fisher, currently a non-executive member of the Board since 1 September 2016 and Chair of the Audit & Risk Committee, has been appointed Non-Executive Chair of the Board, effective from 1 July 2023. Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director.

    Mr. Fisher commented, "On behalf of the Board, I would like to express my excitement for Bionomics' prospects and confidence in the team being assembled. I would also like to thank Errol for his contributions and support during an important period in the Company's transition from an early-stage development organization to a biotechnology company with multiple late-stage product candidates. I am eager to lead Bionomics' Board at this pivotal point for the Company and look forward to working closely with Spyros and the management team in my new role."

    Tim Cunningham of Danforth Associates has been appointed Chief Financial Officer, effective 1 July 2023. This appointment is in continuation to the ongoing expansion of the leadership team that began in 2023 with the appointment of Julie Kerner, Ph.D., as Senior Vice President of Business Operations, and Atul R. Mahableshwarkar, M.D., as the Acting Chief Medical Officer. The Company has also engaged Francisco Bejar as a strategic advisor to head the business development efforts in the U.S. and abroad, whilst Connor Bernstein, Vice President, Strategy and Development, steps down from his role with effect from 30 June 2023.

    "With the addition of multiple U.S.-based and highly accomplished industry executives, we believe we have positioned Bionomics for sustainable growth as we continue to advance our corporate evolution," said Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics. "Collectively, Tim, Julie, and Atul bring over 50+ years of experience in the biopharma sector, and diverse expertise in developing and commercializing drug products. I am confident that their complementary skill sets will be instrumental in leading the Company into a new era focused on the fiscally efficient advancement of our late-stage programs. I would like to thank Connor for his contributions to the Company and wish him well for the future, as well as Adrian Hinton, Acting CFO for the last four years who will continue supporting the Company as a Financial Controller. In addition, I look forward to working with Alan in his new role as Chair of the Board and would like to thank Errol for his many contributions to Bionomics."

    New and Recent Appointee Bios

    Mr. Fisher is an experienced corporate advisor and public company director, with a proven track record for implementing strategies that enhance shareholder value. His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. He is currently a Non-Executive Director and Chair of Centrepoint Alliance Limited (ASX:CAF) and Non-Executive Director and Chair of the Audit and Risk Committee of Thorney Technologies Limited (ASX:TEK).

    Mr. Cunningham has served as a Chief Financial Officer Consultant at Danforth, a strategic finance and operations firm with a focus on life sciences companies, since September 2020, where he provides chief financial officer consulting services to both public and private pharma and biotechnology companies. Prior to joining Danforth, Mr. Cunningham served as Chief Financial Officer at Organogenesis (NASDAQ:ORGO), where he took the company public and raised over US$250M in equity and debt financing to facilitate the company's growth. He has held leadership positions with several different public and private companies over the course of his career, which began at KPMG in NY followed by PwC Boston. Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the state of Florida.

    Dr. Kerner brings over 15 years of experience where under her leadership companies created portfolio and platform strategies, built new therapeutic areas, filed over 10 IND/CTAs, conducted proof of concept and Phase 3 trials, and launched multiple therapeutics. Dr. Kerner has worked at Biogen, AVROBIO, Wave Life Sciences and most recently Fulcrum Therapeutics and Aliada Therapeutics, where she was responsible for driving pipeline strategy and program leadership. Dr. Kerner is a board member of Newton Wellesley Hospital, National Braille Press, and the U.S. Neuroacanthocytosis advocacy, Inc.

    Dr. Mahableshwarkar is a board-certified psychiatrist with over 20 years of strategic, developmental, and regulatory experience in large global and small startup companies who have submitted INDs and NDAs leading to drug approvals. He has had leadership roles as Chief Medical Officer and Senior Vice President/Vice President for Clinical Development in Emalex Biosciences and BlackThorn Therapeutics, where he provided strategy and oversight of the clinical program from proof of concept to drug approval.

    The company has also engaged Mr. Francisco Bejar as a Strategic Business Development Advisor to lead the Company's partnering efforts for BNC210, the company's preclinical assets (KV3 and Nav1.7/1.8 programs) and our legacy oncology portfolio both in the U.S. and ex-U.S.

    For more detailed appointee bios, visit the Bionomics website.

    Released on authority of the Board of Directors

    FOR FURTHER INFORMATION PLEASE CONTACT:

    GeneralInvestor RelationsInvestor Relations
    Ms. Suzanne IrwinKevin GardnerChris Calabrese
    Company Secretary[email protected][email protected]
    +61 8 8150 7400  
    [email protected]  
       

    About Bionomics Limited

    Bionomics ((ASX:BNO, NASDAQ:BNOX) is a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system ("CNS") disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease and other central nervous system conditions.

    www.bionomics.com.au



    Primary Logo

    Get the next $BNOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BNOX
    $ORGO

    CompanyDatePrice TargetRatingAnalyst
    Organogenesis Holdings Inc.
    $ORGO
    6/28/2024$5.00Buy
    Lake Street
    Organogenesis Holdings Inc.
    $ORGO
    2/7/2024$5.00Overweight
    Cantor Fitzgerald
    Bionomics Limited
    $BNOX
    9/28/2023$7.00 → $10.00Buy
    Maxim Group
    Bionomics Limited
    $BNOX
    9/28/2023$8.00Neutral → Buy
    H.C. Wainwright
    Organogenesis Holdings Inc.
    $ORGO
    6/15/2023$5.00Equal-Weight
    Morgan Stanley
    Organogenesis Holdings Inc.
    $ORGO
    5/24/2023$10.00Neutral → Buy
    BTIG Research
    Organogenesis Holdings Inc.
    $ORGO
    11/10/2022Buy → Neutral
    BTIG Research
    Organogenesis Holdings Inc.
    $ORGO
    8/10/2022Outperform → Perform
    Oppenheimer
    More analyst ratings

    $BNOX
    $ORGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

      CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net revenue of $110.0 million for the first quarter of 2024. Net revenue for the first quarter of 2025 consists of: Net revenue from Advanced Wound Care products of $79.9 mill

      5/8/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Supports CMS' Local Coverage Determination Implementation Delay to Review Coverage Policies to Maintain Patient Access with High Quality Evidence of Effectiveness

      CANTON, Mass., April 11, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets supports the U.S. Centers for Medicare & Medicaid Services' (CMS) decision to delay the local coverage determinations (LCDs) for skin substitute grafts/cellular and tissue-based products (CTP) for the treatment of diabetic foot ulcers (DFU) and venous leg ulcers (VLU) to review its coverage policies. "Organogenesis supports an evidence-based approach to coverage and is pleased that CMS has delayed LCD implem

      4/11/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. Management will host a conference call at 5:00 p.m. Eastern Time on May 8th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the telec

      4/7/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNOX
    $ORGO
    Leadership Updates

    Live Leadership Updates

    See more
    • Organogenesis Expands Manufacturing Capacity to Support Future Growth

      CANTON, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, announced plans to expand manufacturing capacity with a long-term lease for a 122,000-square foot state-of-the-art biomanufacturing facility located at 100 Technology Way in Smithfield, Rhode Island. "We are pleased to join the Rhode Island life sciences community as we expand our New England manufacturing capacity to support future growth," said Gary S. Gillheeney, Sr., President, Chief Executive Officer, a

      11/22/24 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. Announces $130 Million Private Placement Offering of Series A Convertible Preferred Stock

      CANTON, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that it has entered into a Subscription Agreement with affiliates of Avista Healthcare Partners ("Investors") for the sale of its Series A Convertible Preferred Stock ("Preferred Stock") in a private placement for gross proceeds of $130 million to the Company, prior to deducting placement agent commissions, fees and other offering expenses. The Company intends to use the net proceeds from the

      11/12/24 4:01:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

      Alan Fisher appointed Chair of the Board of DirectorsTim Cunningham joins as Chief Financial Officer ADELAIDE, Australia and CAMBRIDGE, Mass., July 03, 2023 (GLOBE NEWSWIRE) -- Bionomics Limited (NASDAQ:BNOX, ASX: BNO))) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced key leadership updates to drive its ongoing transformation to a U.S.-focused company, streamline its allocation of capital, and support its next stage of strategic growth. Alan Fisher, currently a non-executive me

      7/3/23 6:00:00 AM ET
      $BNOX
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNOX
    $ORGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 271 shares, decreasing direct ownership by 0.14% to 189,525 units (SEC Form 4)

      4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

      3/12/25 4:29:29 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Driscoll Michael Joseph sold $127,535 worth of shares (25,000 units at $5.10), decreasing direct ownership by 13% to 166,879 units (SEC Form 4)

      4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

      3/6/25 9:08:33 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vice President, Strategy Cavorsi Robert covered exercise/tax liability with 667 shares, decreasing direct ownership by 0.35% to 189,796 units (SEC Form 4)

      4 - Organogenesis Holdings Inc. (0001661181) (Issuer)

      3/4/25 5:01:25 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNOX
    $ORGO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on Organogenesis with a new price target

      Lake Street initiated coverage of Organogenesis with a rating of Buy and set a new price target of $5.00

      6/28/24 8:20:16 AM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Organogenesis with a new price target

      Cantor Fitzgerald initiated coverage of Organogenesis with a rating of Overweight and set a new price target of $5.00

      2/7/24 6:56:39 AM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group reiterated coverage on Bionomics Limited with a new price target

      Maxim Group reiterated coverage of Bionomics Limited with a rating of Buy and set a new price target of $10.00 from $7.00 previously

      9/28/23 12:57:32 PM ET
      $BNOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNOX
    $ORGO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Organogenesis Holdings Inc.

      SC 13D - Organogenesis Holdings Inc. (0001661181) (Subject)

      11/19/24 4:05:57 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Organogenesis Holdings Inc.

      SC 13D/A - Organogenesis Holdings Inc. (0001661181) (Subject)

      11/14/24 8:09:56 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Organogenesis Holdings Inc.

      SC 13G/A - Organogenesis Holdings Inc. (0001661181) (Subject)

      11/14/24 3:35:42 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNOX
    $ORGO
    Financials

    Live finance-specific insights

    See more
    • Organogenesis Holdings Inc. Reports First Quarter 2025 Financial Results

      CANTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Results Summary: Net revenue of $86.7 million for the first quarter of 2025, a decrease of $23.3 million compared to net revenue of $110.0 million for the first quarter of 2024. Net revenue for the first quarter of 2025 consists of: Net revenue from Advanced Wound Care products of $79.9 mill

      5/8/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2025 Financial Results on May 8, 2025

      CANTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that first quarter of fiscal year 2025 financial results will be reported after the market closes on Thursday, May 8th. Management will host a conference call at 5:00 p.m. Eastern Time on May 8th to discuss the results of the quarter, and to provide a corporate update with a question and answer session. Those who would like to participate may access the live webcast here, or access the telec

      4/7/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. Reports Fourth Quarter 2024 Financial Results

      CANTON, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care, and surgical and sports medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2024. Fourth Quarter 2024 Financial Results Summary: Net revenue of $126.7 million for the fourth quarter of 2024, an increase of $27.0 million compared to net revenue of $99.7 million for the fourth quarter of 2023. Net revenue for the fourth quarter of 2024 consists of: Net revenue from A

      2/27/25 4:05:00 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BNOX
    $ORGO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Organogenesis Holdings Inc.

      10-Q - Organogenesis Holdings Inc. (0001661181) (Filer)

      5/8/25 4:11:48 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Organogenesis Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Organogenesis Holdings Inc. (0001661181) (Filer)

      5/8/25 4:07:25 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Organogenesis Holdings Inc.

      PRE 14A - Organogenesis Holdings Inc. (0001661181) (Filer)

      4/29/25 5:15:35 PM ET
      $ORGO
      Biotechnology: Pharmaceutical Preparations
      Health Care